Harmony Biosciences (HRMY) Tops Q4 EPS by 1c

Harmony Biosciences (NASDAQ: HRMY) reported Q4 EPS of $0.73, $0.01 better than the analyst estimate of $0.72. Revenue for the quarter came in at $168.4 million versus the consensus estimate of $169.65 million.

For earnings history and earnings-related data on Harmony Biosciences (HRMY) click here.

You May Also Be Interested In

• Etsy upgraded to buy at BofA on durable growth, buyback potential
• JPMorgan Downgrades Rockwool (ROCKB:DC) (RKWBF) to Neutral
• UBS Downgrades Vicinity Centers (VCX:AU) (CNRAF) to Neutral